About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.


The impact of medicine use in pregnancy is difficult to study. There has been increasing attention to how particular medicines can affect children’s neurodevelopment. The ConcePTION project recently published an inventory of European data sources that can support research on the neurodevelopmental effects of exposure to medicines in pregnancy.  | READ MORE >>
Interested in the ethics of research on medications during pregnancy? Marieke Hollestelle will be presenting her talk, “Ethical Considerations When Using Real World Data for Research on Medication Safety in Pregnancy" at an event on 1 December 2022, organised by Harvard Program on Perinatal and Pediatric Pharmacoepidemiology (H4P). Her presentation will be followed by discussion with Drs. Krista Huybrechts, Ameet Sarpatwari, and Sonia Hernandez-Diaz.  | READ MORE >>
Today marks the start of #MedSafetyWeek, putting the spotlight on how patients and health care providers can make safety work! One challenge for pregnancy and breastfeeding is the fact that pharmacovigilance data is heterogenous and scattered, making it hard to generate evidence. Another is the fact that the information that is out there about what is safe and what is not is often conflicting. Making it difficult for women and their doctors to make informed decisions about medicines in pregnancy. But just like everyone else, pregnant women sometimes need to take medicines. Sometimes the reason has nothing to do with pregnancy, like headaches, allergies or chronic illness. Sometimes health problems start or get worse when a woman is pregnant, like diabetes, morning sickness or high blood pressure. Sometimes women take medicines before they know that they are pregnant. If women and health-care professionals report medicine use during pregnancy, that information can help women make informed decisions about the benefits and risks of different treatments!  | READ MORE >>


We need to know how medicine use in #pregnancy can affect children’s #neurodevelopment. Want to know more about our inventory of European data sources that can support research?

👉 https://www.imi-conception.eu/news-details/?news_id=1031

#MedSafety #pharmacovigilance #MaternalHealth

From Inception to ConcePTION: Genesis of a network to support better monitoring and communication of medication safety during #pregnancy and #breastfeeding #MedicineSafety #MaternalHealth 👇

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.


The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.